Cellular Effect
| Cell Line | Activity | Value | Description | Reference |
|---|---|---|---|---|
| H9 | IC50 | 0.03 μM | Inhibition of HIV-1 protease in a cell culture assay using HIV-1 IIIB infected H9 cells. | [PMID: 9719600] |
| MT2 | EC50 | 0.17 μM | Antiviral activity against HIV1 LAI infected in human MT2 cells by MTT assay | [PMID: 20439612] |
| MT2 | EC50 | 0.3 μM | Antiviral activity against HIV2 EHO infected in human MT2 cells by MTT assay | [PMID: 20439612] |
| MT2 | EC50 | 0.33 μM | Antiviral activity against HIV2 ROD infected in human MT2 cells by MTT assay | [PMID: 20439612] |
| MT2 | CC50 | 54.1 μM | Cytotoxicity against human MT2 cells after 7 days by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.022 μM | Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.029 μM | Antiviral activity against HIV1 expressing protease L10I/L24I/M46I/V82I/I84V mutant infected in human MT4 cells selected after 50 passages of GRL-216 by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.037 μM | Antiviral activity against HIV1 expressing protease L10F/M46L/I50V/A71Vmutant infected in human MT4 cells selected at 1 uM of GRL-286 by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.039 μM | Antiviral activity against HIV1 expressing protease L10F/D30N/K45I/A71V/T74S mutant infected in human MT4 cells selected at 5 uM of nelfinavir by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.042 μM | Antiviral activity against HIV1 expressing protease L10F/M46M,I/Q61Q mutant infected in human MT4 cells selected at 1 uM of GRL-396 by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.095 μM | Antiviral activity against HIV1 expressing protease L10F/M46I/T91S mutant infected in human MT4 cells selected at 1 uM of GRL-246 by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.22 μM | Antiviral activity against HIV1 expressing protease L10F/M46I/I50V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of amprenavir by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.31 μM | Antiviral activity against HIV1 expressing protease L10F/M46I/I54V/V82A mutant infected in human MT4 cells selected at 5 uM of Lopinavir by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.32 μM | Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 0.41 μM | Antiviral activity against HIV1 expressing protease L23I/E34Q/K43I/M46I/I50L/G51A/L63P/A71V/V82A/T91A mutant infected in human MT4 cells selected at 5 uM of atazanavir by MTT assay | [PMID: 20439612] |
| MT4 | EC50 | 184 nM | Antiviral activity against wild-type HIV1 pNL4-3 infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay | [PMID: 18212102] |
| MT4 | EC50 | 204 nM | Antiviral activity against wild-type HIV1 RF infected in human MT4 cells assessed as reduction in viral cytopathogenicity treated 1 hr post infection measured 5 days post infection in absence of human serum by MTT assay | [PMID: 18212102] |
| MT4 | EC50 | 310 nM | Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 10% human serum by MTS assay | [PMID: 17620375] |
| MT4 | EC50 | 360 nM | Antiviral activity against HIV1 A17 infected in human MT4 cells harboring protease L10F, V32I, M46I, I47V, Q58E, and I84V mutation derived from viral passages with Lopinavir assessed as reduction in viral cytopathogenicity treated 1 hr post infection meas | [PMID: 18212102] |
19 records · Scroll to view more